MX2024000542A - Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden. - Google Patents

Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden.

Info

Publication number
MX2024000542A
MX2024000542A MX2024000542A MX2024000542A MX2024000542A MX 2024000542 A MX2024000542 A MX 2024000542A MX 2024000542 A MX2024000542 A MX 2024000542A MX 2024000542 A MX2024000542 A MX 2024000542A MX 2024000542 A MX2024000542 A MX 2024000542A
Authority
MX
Mexico
Prior art keywords
seq
peptides
inhibit
compositions
linear peptides
Prior art date
Application number
MX2024000542A
Other languages
English (en)
Spanish (es)
Inventor
Nieto Gerardo Enrique Guillén
Blanco Sonia Gonzalez
López Luis Javier González
Pérez Vladimir Armando Besada
Rodríguez Silvio Ernesto Perea
Negrin Yasser Perera
Pérez Hilda Elisa Garay
González Yordanka Masforrol
Acosta Osvaldo Reyes
Menéndez Evelin Caballero
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2024000542A publication Critical patent/MX2024000542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
MX2024000542A 2021-07-09 2022-07-07 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden. MX2024000542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Publications (1)

Publication Number Publication Date
MX2024000542A true MX2024000542A (es) 2024-02-02

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000542A MX2024000542A (es) 2021-07-09 2022-07-07 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden.

Country Status (11)

Country Link
US (1) US20240317827A1 (https=)
EP (1) EP4368710A1 (https=)
JP (1) JP2024534231A (https=)
KR (1) KR20240032882A (https=)
CN (1) CN117795064A (https=)
AR (1) AR126388A1 (https=)
AU (1) AU2022308094A1 (https=)
CA (1) CA3225387A1 (https=)
CU (1) CU24766B1 (https=)
MX (1) MX2024000542A (https=)
WO (1) WO2023280330A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides

Also Published As

Publication number Publication date
CU24766B1 (es) 2025-08-13
WO2023280330A1 (es) 2023-01-12
JP2024534231A (ja) 2024-09-18
CU20210058A7 (es) 2023-02-13
US20240317827A1 (en) 2024-09-26
KR20240032882A (ko) 2024-03-12
AU2022308094A1 (en) 2024-02-01
EP4368710A1 (en) 2024-05-15
AR126388A1 (es) 2023-10-11
CN117795064A (zh) 2024-03-29
CA3225387A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
EP2426139B1 (en) CXCR4 antagonist and use thereof
CL2021000550A1 (es) Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460)
KR20190016026A (ko) 프로그램 된 세포사멸을 유도하는 cd47의 효능제 및 이의 프로그램 된 세포사멸 결함과 관련된 질병 치료에의 용도
US8722616B2 (en) Anti-HIV peptides and methods of use thereof
MX2024015050A (es) L-asparaginasa modificada
US20160068570A1 (en) Anti-tumor polypeptides and method for preparing anti-tumor drugs comprisng the same
UA124577C2 (uk) Пептид для лікування раку
JP2020533023A (ja) 病気の治療のためのポリペプチド
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
MX2024000542A (es) Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden.
MX2022001717A (es) Aplicacion de polipeptido o derivado del mismo.
AR123189A1 (es) VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS
AR074388A1 (es) Un peptido inhibidor del factor de necrosis tumoral alfa, un proceso para la preparacion de dicho peptido y una composicion farmaceutica que comprende dicho peptido
US20200368338A1 (en) Conjugate of wt1-derived peptides and composition comprising the same
AR112785A1 (es) Composición de péptidos asociados a tumores proliferativos e inmunógeno anti-cáncer relacionado para el tratamiento de cánceres de pulmón y otros cánceres
AR134636A1 (es) Compuestos peptídicos híbridos que tienen un residuo de lisina modificado
MX2018012716A (es) Peptidos bioactivos pegilados y usos de los mismos.
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
AR132194A1 (es) PROTEÍNAS DIRIGIDAS A Ab Y MÉTODOS DE USO
DE60120187T2 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CU20200110A7 (es) Péptidos para el tratamiento de infecciones respiratorias de origen viral
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
BR112022011540A2 (pt) Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero
AR132931A1 (es) PROTEÍNAS DE UNIÓN A AGONISTAS DE RECEPTOR DE LINFOTOXINA b